Clinical Trials Logo

Clinical Trial Summary

Addison's disease is a rare condition which in most cases is caused by autoimmune destruction of the adrenals, leading to deficiency of cortisol, aldosterone and adrenal androgens. Unrecognized the disease is life threatening, but with proper treatment patients can live near normal lives.

The conventional glucocorticoid replacement therapy renders the cortisol levels unphysiological, which may cause symptoms and long-term complications. Glucocorticoid replacement therapy is technically feasible by continuous subcutaneous hydrocortisone infusion (CSHI), and can mimic the normal diurnal cortisol rhythm. This study aims to further evaluate CSHI treatment in terms of metabolic effects, effects on health-related quality-of-life and sleep in an 8 months randomised open label clinical trial with crossover design.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01063569
Study type Interventional
Source Haukeland University Hospital
Contact
Status Completed
Phase Phase 2/Phase 3
Start date February 2010
Completion date December 2012

See also
  Status Clinical Trial Phase
Completed NCT00444119 - Survey in Patients With Chronic Adrenal Insufficiency in Germany N/A
Completed NCT01452893 - Counterregulatory Hormone Production in Adrenal Insufficiency and Diabetes Type I N/A
Recruiting NCT05350020 - The Effects of Two Brands of Hydrocortisone Injected Intramuscularly Into Deltoid and Thigh Muscles Phase 4
Not yet recruiting NCT01657123 - Exercise Capacity and Recovery in Addison's Disease N/A
Not yet recruiting NCT04252001 - Growing up With the Young Endocrine Support System (YESS!) N/A
Completed NCT00688987 - The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight Regulation N/A
Completed NCT00004313 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency Phase 3